This clinical trial is focused on studying the effects of a treatment for Atopic Dermatitis, a common skin condition that causes red, itchy, and inflamed skin. The treatment being tested is a cream containing Ruxolitinib, which is applied to the skin. The study aims to determine how effective and safe this cream is for adults who have moderate atopic dermatitis and have not responded well to other treatments like topical corticosteroids or topical calcineurin inhibitors.

Participants in the study will be randomly assigned to use either the Ruxolitinib cream or a similar cream without the active ingredient, known as a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the active treatment or the placebo. This helps ensure that the results are unbiased. The study will last for several weeks, during which participants will apply the cream to their skin and attend regular check-ups to monitor their progress and any side effects.

The main goal of the study is to see if the Ruxolitinib cream can significantly improve the symptoms of atopic dermatitis, such as reducing the severity of skin inflammation and itchiness. Participants’ skin condition will be assessed at various points throughout the study to track improvements. The study will also gather information on any side effects experienced by participants to ensure the treatment is safe. This research could potentially lead to a new treatment option for those suffering from moderate atopic dermatitis.